Turnaround time used to be the headline UM metric, and for a defined set of payers, it’s now table stakes: the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) sets a 72-hour floor for expedited requests and 7 calendar days for standard ones. The rule reaches Medicare Advantage organizations, state Medicaid and CHIP fee-for-service and managed care programs, and qualified health plans on the federally facilitated exchanges. For the payers it covers, the rule requires them to publicly report prior authorization metrics, which turns review accuracy from an internal performance indicator into a published one.
Public reporting requirements reveal what happens without that discipline. A January 2026 KFF analysis found that Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024, and 80.7% of appealed denials were partially or fully overturned, a pattern consistent since 2019. A June 2026 HHS OIG report found 95% of appealed skilled nursing facility denials overturned, language OIG itself used to say this “raises concerns” about the initial determinations.
Review quality is the variable that determines whether UM functions as a clinical quality tool or a source of rework, provider abrasion, and regulatory exposure.
What Quality Actually Means in a Clinical Review
“Quality” gets used loosely in UM. Measured precisely, it comes down to four dimensions: the right reviewer, current evidence, first-pass accuracy, and defensible documentation.
The reviewer-match gap is where the industry’s own data is most uncomfortable. In the 2025 AMA Prior Authorization Physician Survey, only 24% of physicians say medical-necessity denials are consistently reviewed by a licensed, qualified clinician, and just 16% say the health plan representative in a peer-to-peer review often or always has the appropriate credentials. The full survey data breaks this down further by specialty and line of business.
First-pass accuracy is what overturn rates, reviewer consistency, and audit scores are actually measuring, and it’s built into accreditation for a reason: URAC’s utilization review standards set the timeframe and process expectations that a defensible review has to meet. Worth noting for a full picture, not just a favorable one: KFF’s own analysis points out that high overturn rates can also reflect incomplete documentation at the initial request, not only reviewer error. That’s a reason complete information capture belongs inside the definition of quality, not outside it.
What Members Gain When the Review Is Right the First Time
An overturned appeal represents care a provider already ordered and a plan later agreed was necessary, just delayed by the extra step of appealing it, as KFF frames it. That delay isn’t neutral. In the 2025 AMA survey, more than 1 in 4 physicians reported that prior authorization led to a serious adverse event for a patient in their care.
Quality protects members in both directions at once: confirming that requested care is evidence-based and appropriate, which is what prior authorization is designed to do as a clinical quality tool, and confirming that appropriate care isn’t needlessly delayed by a review that gets it wrong the first time. Getting both of those directions right, consistently, is what a health plan owes the members whose care depends on the decision.
What Providers Gain: A Peer Worth Talking To
Provider abrasion around prior authorization usually gets treated as a network relations problem. It’s more accurately a quality symptom. Physicians report completing 40 prior authorizations per week on average, and 94% say PA contributes to burnout, according to the AMA. Underneath the volume, the skepticism is specifically about who’s on the other end of the review.
Specialty matching is the structural fix. When peer-to-peer review means a same-specialty physician talking to another physician, the conversation functions as clinical dialogue instead of an obstacle to route around, and a determination that redirects care to a more appropriate option keeps its credibility with the ordering provider. Fewer resubmissions and escalations follow from that one upstream decision: who reviews the case in the first place.
The Economics: You Pay for Review Quality Either Way
A low-quality determination gets paid for three times:
- Once in the original review
- Again in the appeal it triggers
- Third time in downstream exposure
For CMS-0057-F payers, public reporting makes the first two visible to regulators, providers, and members directly; plans outside that scope don’t face public disclosure, but the underlying costs still show up in appeal volume and provider relationships. The third is easy to overlook in a procurement decision built around unit price: KFF’s analysis of post-acute care denials notes that independent review entity reversals can negatively affect a plan’s star ratings.
A quality evaluation looks at what predicts first-pass accuracy before a single case is reviewed:
- URAC or NCQA accreditation
- Depth of a specialty-matched physician panel, all-state licensure
- Documented, audited quality program the partner is willing to show you
How MRIoA Builds Quality Into Every Review
MRIoA has operated as a clinically driven utilization management partner for more than 40 years, built specifically around the reviewer-match and first-pass-accuracy dimensions of quality described in this article. That track record is backed by URAC dual accreditation across Health Utilization Management and Independent Review Organization, NCQA accreditation, HITRUST certification, a network of 700-plus state-matched physician specialists across 150-plus specialties, and licensure in all 50 states.
MRIoA’s tech-enabled workflows streamline intake and case routing, with every determination made by a physician reviewer matched to the case. That structure supports 99%+ quality and 98%+ turnaround-time performance across more than 2.4 million reviews per year, the kind of first-pass accuracy that keeps a plan off the overturn-rate scoreboard rather than on it.
A Midwest Blue Cross Blue Shield plan partnered with MRIoA to eliminate a sizeable medical director review backlog while sustaining more than 98% quality and turnaround-time performance throughout. Health plans, TPAs, and PBMs evaluating a UM partner’s quality program are welcome to schedule a consultation with MRIoA’s clinical review team to benchmark their program’s quality metrics against that standard.
